Across TCGA pan-cancer cohorts, MTND2P26 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of MTND2P26’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where MTND2P26 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MTND2P26 is over-expressed in tumor.
BRCA and HNSC are the cancer types where MTND2P26 tumor–normal differential expression is most reproducible.